PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 730623	FOR FURTHER ACTION	See Form PCT/IPEA/416
International application No. PCT/SG2004/000354	International filing date *(day/month/year)* 26 October 2004	Priority date *(day/month/year)* 27 October 2003

International Patent Classification (IPC) or national classification and IPC

Int. Cl.[7] C07D 417/04, 407/14, 231/44, 307/52, 333/38, 409/12, 307/68; A61K 31/34, 31/381, 31/415, 31/426, 31/427, 31/421; A61P 35/00

Applicant

S*BIO PTE LTD et al

1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 4 sheets, including this cover sheet.
3. This report is also accompanied by ANNEXES, comprising:
   a. [X] *(sent to the applicant and to the International Bureau)* a total of 15 sheets, as follows:
      - [X] sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).
      - [ ] sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.

   b. [ ] *(sent to the International Bureau only)* a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or table related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).
4. This report contains indications relating to the following items:

[X]	Box No. I	Basis of the report
[ ]	Box No. II	Priority
[X]	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
[ ]	Box No. IV	Lack of unity of invention
[X]	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
[ ]	Box No. VI	Certain documents cited
[ ]	Box No. VII	Certain defects in the international application
[ ]	Box No. VIII	Certain observations on the international application

Date of submission of the demand	Date of completion of the report
18 July 2005	11 October 2005
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer K. LEVER Telephone No. (02) 6283 2263

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/SG2004/000354

Box N Basis of the report

1. With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ This report is based on translations from the original language into the following language which is the language of a translation furnished for the purposes of:

☐ international search (under Rules 12.3 and 23.1 (b))

☐ publication of the international application (under Rule 12.4)

☐ international preliminary examination (under Rules 55.2 and/or 55.3)

2. With regard to the elements of the international application, this report is based on (*replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report*):

☐ the international application as originally filed/furnished

☒ the description:

pages **1,2,4,6,8,10-14,17-104** as originally filed/furnished

pages* **3,5,7,9,15,16** received by this Authority on **18 July 2005** with the letter of **14 July 2005**

pages* received by this Authority on with the letter of

☒ the claims:

pages **106,110,113,114,116-132** as originally filed/furnished

pages* as amended (together with any statement) under Article.19

pages* **105,107,107,108,109,109,111,112,115** received by this Authority on **18 July 2005** with the letter of **14 July 2005**

pages* received by this Authority on with the letter of

☐ the drawings:

pages as originally filed/furnished

pages* received by this Authority on with the letter of

pages* received by this Authority on with the letter of

☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.

3. ☐ The amendments have resulted in the cancellation of:

☐ the description, pages

☐ the claims, Nos.

☐ the drawings, sheets/figs

☐ the sequence listing (*specify*):

☐ any table(s) related to the sequence listing (*specify*):

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

☐ the description, pages

☐ the claims, Nos.

☐ the drawings, sheets/figs

☐ the sequence listing (*specify*):

☐ any table(s) related to the sequence listing (*specify*):

* *If item 4 applies, some or all of those sheets may be marked "superseded."*

Box No. I Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application

☒ claims Nos: **1-27, 30-76 in part**

because:

☐ the said international application, or the said claims Nos.
relate to the following subject matter which does not require an international preliminary examination *(specify)*:

☐ the description, claims or drawings *(indicate particular elements below)* or said claims Nos.
are so unclear that no meaningful opinion could be formed *(specify)*:

☐ the claims, or said claims Nos.
are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for said claim Nos. **1-27,30-76 in part**

☐ the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:

the written form
- ☐ has not been furnished
- ☐ does not comply with the standard

the computer readable form
- ☐ has not been furnished
- ☐ does not comply with the standard

☐ the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-*bis* of the Administrative Instructions.

☐ See Supplemental Box for further details.

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1-76 in part	YES
	Claims		NO
Inventive step (IS)	Claims	1-76 in part	YES
	Claims		NO
Industrial applicability (IA)	Claims	1-76 in part	YES
	Claims		NO

2. Citations and explanations (Rule 70.7)

The compounds disclosed in Sheba et al do not fall with in the scope of the current claims.

Sheba et al does not suggest compounds of the current claims.

It is therefore considered that claims 1-76 in part are novel and possess an inventive step.

Claims 1-76 are considered to have Industrial Applicability.

Z is a single bond or a C_1-C_4 hydrocarbon chain containing no more than 1 double or triple bond, optionally substituted with one or more substituents independently selected from the group consisting of C_1-C_4 alkyl;

A is an aromatic ring selected from the group consisting of optionally substituted arylene and optionally substituted heteroarylene, wherein A is not benzimidazole and when Z is a single bond then A is not selected from the group consisting of phenylene and six-membered heteroarylene containing 3 or less than 3 nitrogens;

B is an aromatic ring selected from the group consisting of optionally substituted aryl, and heteroaryl and wherein A and B can not both be phenylene and wherein when Z is a single bond then B is not a bicyclic aryl or bicyclic heteroaryl;.

wherein A and B are connected via a carbon-carbon bond;

R_2 is selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, phenoxy, benzyloxy, COOH, $COOR_4$, SH, $CONHR_4$, NHR_4, $-(CH_2)_nNHCOR_4$, $NHCOR_4$, $NHCOOR_4$ $NHCONHR_4$, $C(=NOH)R_4$, $NHSOR_4$ $NHSO_2R_4$, $-(CH_2)_n-NR_6R_7$, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR_4 and acyl each of which may optionally be substituted, provided that R_2 does not contain the moiety NHCONHCO or $NHCONHSO_2$;

R_3 is selected from the group consisting of H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, phenoxy, benzyloxy, COOH, $COOR_4$, SH, $CONHR_4$, NHR_4, $-(CH_2)_nNHCOR_4$, $NHCOR_4$,

or a pharmaceutically acceptable salt or prodrug thereof, wherein when A is 2,5-oxazolene and Z is a single bond, $R_2 = R_3 = H$, then B is not a phenyl, 4-Cl-phenyl, 4-CH_3-O-phenyl or 4-NO_2-phenyl.

A useful group of compounds within the scope of Formula (I) are those compounds of Formula (Ia)



Formula (Ia)

wherein

Z is a single bond or a C_1-C_4 hydrocarbon chain which may contain 0 to 1 double or triple bonds, unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_1-C_4 alkyl;

A is an aromatic ring selected from the group consisting of optionally substituted arylene and optionally substituted heteroarylene, wherein A is not benzimidazole and when Z is a single bond then A is not selected from the group consisting of phenylene and six-membered heteroarylene containing 3 or less than 3 nitrogens;

B is an aromatic ring selected from the group consisting of aryl and heteroaryl and heteroarylene and wherein A and B can not both be phenylene and wherein when Z is a single bond then B is not a bicyclic aryl or bicyclic heteroaryl;

wherein A and B are connected via a carbon-carbon bond;

R_2 is selected from C_1-C_{10} alkyl, alkenyl, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C_4-C_9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), arylalkyl (e.g. benzyl), heteroarylalkyl (e.g. pyridyimethyl), hydroxyl, hydroxyalkyl, alkoxy, amino, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylsulfonyl, arylsulfonyl, aminosulfonyl, -C(O)OR_4, -C(O)OH, -SH, -CONHR_4,

R_8 and R_9 are the same or different and independently selected from the group consisting of H, C_1-C_6 alkyl, C_4-C_9 cycloalkyl, C_4-C_9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl,

m is an integer from 0 to 4;

or a pharmaceutically acceptable salt or prodrug thereof, wherein when A is 2,5-oxazolene and Z is a single bond, R_2 = R_3 = H, then B is not a phenyl, 4-Cl-phenyl, 4-CH_3-O-phenyl or 4-NO_2-phenyl.

In further embodiments there are disclosed hydroxamate compounds of Formula (Ib):



Formula (Ib)

wherein

Z is a single bond or a C_1-C_4 hydrocarbon chain which may contain 0 to 1 double bond or triple bond, unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_1-C_4 alkyl;

A is an optionally substituted five-membered heteroarylene;

B is an aromatic ring which is selected from the group consisting of aryl, and heteroaryl; wherein when Z is a single bond then B is not a bicyclic aryl or bicyclic heteroaryl;

wherein A and B are connected via a carbon-carbon bond;

R_2 is selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl,

n is an integer from 0 to 6;

m is an integer from 0 to 4;

or a pharmaceutically acceptable salt or prodrug thereof wherein when A is 2,5-oxazolene and Z is a single bond, $R_2 = R_3 = H$, then B is not a phenyl, 4-Cl-phenyl, 4-CH_3-O-phenyl or 4-NO_2-phenyl.

In a particularly preferred embodiment of the compounds of Formula (Ib) the B moiety is attached to the 3rd or 4th position relative to Z of ring A.

In yet a further embodiment of the compounds of Formula (I) there are disclosed compounds of the Formula (Ic) :



Formula (Ic)

wherein

Z is a single bond or a C_1-C_4 hydrocarbon chain which may contain 0 to 1 double bond or triple bond, unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_1-C_4 alkyl;

A is a six-membered aromatic ring which is selected from the group consisting of optionally substituted arylene or optionally substituted heteroarylene and when Z is a single bond then A is not selected from the group consisting of phenylene and six-membered heteroarylene containing 3 or less than 3 nitrogens;

B is an aromatic ring and is attached to the 3rd or 4th position relative to Z of ring A selected from the group consisting of aryl, and heteroaryl and wherein A and B can not both be phenylene;

wherein A and B are connected via a carbon-carbon bond;

p is preferably 0 or 1, most preferably 0.

In another preferred embodiment the invention provides compounds of Formula (Ig):



Formula (Ig)

wherein q is an integer from 0 to 4, and X, Y, R_2 and R_3 are as described for Formula (I).

R_2 is preferably selected from the group consisting of:

$-NH_2$,

$-(CH_2)_nNHCOR_4$,

$-NHSO_2R_4$,

$-NR_4$,

$-(CH_2)_nNR_6R_7$.

- arylalkyl,

- hetercarylalkyl,

each of which may be optionally substituted

wherein n is an integer from 0 to 6 and R_4, R_6 and R_7 are as described for Formula (I), or a pharmaceutically acceptable salt or prodrug thereof.

q is preferably 0 or 1, most preferably 0.

In another preferred embodiment the invention provides compounds of Formula (Ih):



Formula (Ih)

wherein q is an integer from 0 to 4, and X, Y, R_2 and R_3 are as described for Formula (I).

R_2 is preferably selected from the group consisting of:

$-NH_2$,

$-(CH_2)_nNHCOR_4$,

$-NHSO_2R_4$,

$-NR_4$,

$-(CH_2)_nNR_6R_7$.

- arylalkyl,

- heteroarylalkyl,

each of which may be optionally substituted

wherein n is an integer from 0 to 6 and R_4, R_6 and R_7 are as described for Formula (I), or a pharmaceutically acceptable salt or prodrug thereof.

q is preferably 0 or 1, most preferably 0.

In another preferred embodiment the invention provides a compound of Formula (Ii):



Formula (Ii)

wherein X, Y, R_2 and R_3 are as described for Formula (I)

. R_2 is preferably selected from the group consisting of:

$-NH_2$,

$-(CH_2)_nNHCOR_4$,

$-NHSO_2R_4$,

$-NR_4$,

$-(CH_2)_nNR_6R_7$.

What is claimed is:

1. A compound of the Formula (I)



Formula (I)

wherein

Z is a single bond or a C_1-C_4 hydrocarbon chain containing no more than 1 double or triple bond, optionally substituted with one or more substituents independently selected from the group consisting of C_1-C_4 alkyl;

A is an aromatic ring selected from the group consisting of optionally substituted arylene and optionally substituted heteroarylene, wherein A is not benzimidazole and when Z is a single bond then A is not selected from the group consisting of phenylene and six-membered heteroarylene containing 3 or less than 3 nitrogens;

B is an aromatic ring selected from the group consisting of aryl, and heteroaryl and wherein A and B can not both be phenylene and wherein when Z is a single bond then B is not a bicyclic aryl or bicyclic heteroaryl;

wherein A and B are connected via a carbon-carbon bond;

R_2 is selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, phenoxy, benzyloxy, COOH, $COOR_4$, SH, $CONHR_4$, NHR_4, $-(CH_2)_nNHCOR_4$, $NHCOR_4$, $NHCOOR_4$ $NHCONHR_4$, $C(=NOH)R_4$, $NHSOR_4$ $NHSO_2R_4$, $-(CH_2)_n-NR_6R_7$, alkoxycarbonyl,

cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl; each of which may be optionally substituted;

each R_8 and R_9 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl; each of which may be optionally substituted;

n is an integer from 0 to 6,

m is an integer from 0 to 4;

or a pharmaceutically acceptable salt or prodrug thereof,

wherein when A is 2,5-oxazolene and Z is a single bond, $R_2 = R_3 = H$, then B is not a phenyl, 4-Cl-phenyl, 4-CH_3-O-phenyl or 4-NO_2-phenyl.

2. A compound according to claim 1 having the Formula (Ia)



Formula (Ia)

wherein

Z is a single bond or a C_1-C_4 hydrocarbon chain which may contain 0 to 1 double or triple bonds, unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_1-C_4 alkyl;

A is an aromatic ring selected from the group consisting of optionally substituted arylene and optionally substituted heteroarylene, wherein A is not benzimidazole and when Z is a single bond then A is not selected from the group consisting of phenylene and six-membered heteroarylene containing 3 or less than 3 nitrogens;

B is an aromatic ring selected from the group consisting of aryl, and heteroaryl

and wherein A and B can not both be phenylene and wherein when Z is a single bond then B is not a bicyclic aryl or bicyclic heteroaryl;

wherein A and B are connected via a carbon-carbon bond;

R_2 is selected from C_1-C_{10} alkyl, alkenyl, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C_4-C_9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), arylalkyl (e.g. benzyl), heteroarylalkyl (e.g. pyridylmethyl), hydroxyl, hydroxyalkyl, alkoxy, amino, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylsulfonyl, arylsulfonyl, aminosulfonyl, -C(O)OR_4, -C(O)OH, -SH, -CONHR_4, -NHCONHR_4, C(=NOH)R_4, -C(O)C(O)OR_4, C(O)CONHR_4, CON(R_5)OR_4, COCON(R_4)OR_4, NHCOR_4, and acyl; each of the above is unsubstituted or optionally substituted with one or more substituents independently selected from the group consisting of: halogen; =O; =S; -CN; and $-NO_2$; and alkyl, alkenyl, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, hydroxyl, hydroxyalkyl, alkoxy, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylsulfonyl, arylsulfonyl, aminosulfonyl, -C(O)OR_5, -C(O)OH, -SH, -C(O)C(O)OR_5, C(O)CONHR_5, CON(R_5)OR_5, COCON(R_5)OR_5, NHCOR_5, and acyl; wherein R_2 does not contain the moiety NHCONHCO or $NHCONHSO_2$;

R_3 is selected from H, C_1-C_{10} alkyl, alkenyl, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C_4-C_9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), arylalkyl (e.g. benzyl), heteroarylalkyl (e.g. pyridylmethyl), hydroxyl, hydroxyalkyl, alkoxy, amino, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylsulfonyl, arylsulfonyl, aminosulfonyl, -C(O)OR_4, -C(O)OH, -SH, -CONHR_4, -NHCONHR_4, C(=NOH)R_4, -C(O)C(O)OR_4, C(O)CONHR_4, CON(R_5)OR_4, COCON(R_4)OR_4, NHCOR_4, and acyl; each of the above is unsubstituted or optionally substituted with one or more substituents independently selected from the group consisting of: halogen; =O; =S; -CN; and $-NO_2$; and alkyl, alkenyl, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, hydroxyl, hydroxyalkyl, alkoxy, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylsulfonyl, arylsulfonyl, aminosulfonyl, -C(O)OR_5, -C(O)OH, -SH, -C(O)C(O)OR_5, C(O)CONHR_5, CON(R_5)OR_5, COCON(R_5)OR_5, NHCOR_5, and acyl; wherein R_3 does not contain the moiety NHCONHCO or $NHCONHSO_2$;

or R_2 and R_3 together with portion of ring B may form a non-aromatic ring fused to B;

X and Y are the same or different and independently selected from the group consisting of: H, halo, C_1 -C_4 alkyl, such as CH_3 and CF_3, NO_2, OR_4, SR_4, $C(O)R_6$, CN, and NR_8R_9;

R_4 is selected from H, C_1-C_4 alkyl, heteroalkyl, aryl, heteroaryl, acyl;

R_5 is selected from H, C_1-C_4 alkyl;

R_8 and R_9 are the same or different and independently selected from the group consisting of H, C_1-C_6 alkyl, C_4-C_9 cycloalkyl, C_4-C_9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl;

m is an integer from 0 to 4;

or a pharmaceutically acceptable salt or prodrug thereof,

wherein when A is 2,5-oxazolene and Z is a single bond, $R_2 = R_3 = H$, then B is not a phenyl, 4-Cl-phenyl, 4-CH_3-O-phenyl or 4-NO_2-phenyl.

3. A compound according to claim 1 or 2 having the Formula (Ib)



Formula (Ib)

wherein

Z is a single bond or a C_1-C_4 hydrocarbon chain which may contain 0 to 1 double bond or triple bond, unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_1-C_4 alkyl;

A is an optionally substituted five-membered heteroarylene;

B is an aromatic ring which is selected from the group consisting of aryl, and heteroaryl; wherein when Z is a single bond then B is not a bicyclic aryl or bicyclic heteroaryl;

R_5 is selected from H, C_1-C_4 alkyl;

each R_6 and R_7 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl each of which may be optionally substituted;

R_8 and R_9 are the same or different and are independently selected from the group consisting of H, C_1-C_6 alkyl, C_4-C_9 cycloalkyl, C_4-C_9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl;

n is an integer from 0 to 6;

m is an integer from 0 to 4;

or a pharmaceutically acceptable salt or prodrug thereof,

wherein when A is 2,5-oxazolene and Z is a single bond, $R_2 = R_3 = H$, then B is not a phenyl, 4-Cl-phenyl, 4-CH_3-O-phenyl or 4-NO_2-phenyl.

4. A compound according to claim 1 or 2 having the compound of Formula (Ic):



Formula (Ic)

wherein

Z is a single bond or a C_1-C_4 hydrocarbon chain which may contain 0 to 1 double bond or triple bond, unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_1-C_4 alkyl;

A is a six-membered aromatic ring which is selected from the group consisting of optionally substituted arylene or optionally substituted heteroarylene and when Z is a single bond then A is not selected from the group consisting of phenylene and six-membered hetercarylene containing 3 or less than 3 nitrogens;

B is an aromatic ring and is attached to the 3rd or 4th position relative to Z of ring A selected from the group consisting of aryl, and heteroaryl and wherein A and B can not both be phenylene;

wherein A and B are connected via a carbon-carbon bond;

R_2 is selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, phenoxy, benzyloxy, COOH, $COOR_4$, SH, $CONHR_4$, NHR_4, $-(CH_2)_nNHCOR_4$, $NHCOR_4$, $NHCOOR_4$ $NHCONHR_4$, $C(=NOH)R_4$, $NHSOR_4$ $NHSO_2R_4$, $-(CH_2)_n-NR_6R_7$, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR_4 and acyl; each of which may optionally be substituted, wherein R_2 does not contain the moiety NHCONHCO or $NHCONHSO_2$;

R_3 is selected from the group consisting of H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, phenoxy, benzyloxy, COOH, $COOR_4$, SH, $CONHR_4$, NHR_4, $-(CH_2)_nNHCOR_4$, $NHCOR_4$, $NHCOOR_4$ $NHCONHR_4$, $C(=NOH)R_4$, $NHSOR_4$ $NHSO_2R_4$, $-(CH_2)_nNR_6R_7$, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR_4 and acyl; each of which may optionally be substituted wherein R_3 does not contain the moiety NHCONHCO or $NHCONHSO_2$;

X and Y are the same or different and independently selected from H, halo, C_1-C_4 alkyl, such as CH_3 and CF_3, NO_2, OR_4, SR_4, $C(O)R_5$, CN, and NR_8 R_9 ;

R_4 is selected from H, C_1-C_4 alkyl, heteroalkyl, aryl, heteroaryl, acyl;



Formula (If)

wherein B is a 5-membered heteroarylene, p is an integer from 0 to 3 and X, Y, R_2 and R_3 are the same as in claim 1.

8. A compound according to claim 1 of the Formula (Ig):



Formula (Ig)

wherein q is an integer from 0 to 4 and X, Y, R_2 and R_3 are the same as in claim 1.

9. A compound according to claim 1 of the Formula (Ih):



Formula (Ih)

wherein q is an integer from 0 to 4 and X, Y, R_2 and R_3 are the same as in claim 1.

10. A compound according to claim 1 of the Formula (Ii):